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Introduction {#sec005}
============

Pregnancy- and peri-partum-related critical illness occurs at a frequency of 0.7 to 7.6 cases per 1,000 live births in developed countries \[[@pone.0208563.ref001],[@pone.0208563.ref002]\], and leads to death for 3--14% of affected women \[[@pone.0208563.ref001],[@pone.0208563.ref003],[@pone.0208563.ref004]\]. Determination of the risk of a woman becoming critically ill or dying is helpful to better anticipate and possibly prevent serious illness and to guide therapeutic decision-making. In clinical research, groups of characteristics that together predict an outcome can be used to help account for differences between patients, when you wish to estimate the influence of some new factor on a clinical outcome such as death \[[@pone.0208563.ref005]\].

A number of risk prediction models have been developed for outpatients, hospitalized patients, and those who are critically ill. The simplified acute physiology score (SAPS) \[[@pone.0208563.ref006]\], acute physiology and chronic health evaluation score (APACHE I, II, III, IV) \[[@pone.0208563.ref007]\], the mortality prediction model (MPM) \[[@pone.0208563.ref008],[@pone.0208563.ref009]\], and sequential organ failure assessment (SOFA) scores \[[@pone.0208563.ref010]\] were originally designed to predict mortality in a general adult intensive care unit (ICU) populations.

These and other prediction models have been applied to pregnant and postpartum women, either in the ICU or in a general ward; however, their performance characteristics have generally not been determined among pregnant and postpartum women \[[@pone.0208563.ref011]\]. Within obstetrics, a limited number of risk prediction models have been developed for specific obstetric conditions (e.g. preeclampsia, postpartum hemorrhage) \[[@pone.0208563.ref012],[@pone.0208563.ref013]\]. Optimal prediction models for unselected, broad cohorts of pregnant and postpartum patients have not been well summarized and previous reviews have concluded that existing *comorbidity* indices have modest predictive ability for obstetric patients \[[@pone.0208563.ref014]--[@pone.0208563.ref016]\]. While risk prediction models developed from non-pregnant and postpartum populations have been adopted in clinical research for obstetric patients \[[@pone.0208563.ref011]\], they may have important limitations due to a combination of unique conditions leading to pregnancy-related critical illness and/or death---the typically young age of pregnant patients, and physiological changes specific to pregnancy that may be different from other patient populations. Previously published studies show that non-specific risk prediction models tend to overestimate mortality when applied to pregnant and postpartum women \[[@pone.0208563.ref014],[@pone.0208563.ref017]\]. There is no prior systematic review of this literature exploring the validity of risk prediction models for mortality among pregnant and postpartum critically ill women admitted to acute care hospitals.

Therefore, we aimed to systematically review and meta-analyze risk prediction models for maternal mortality in hospitalized and critically ill pregnant and postpartum women.

Methods {#sec006}
=======

This meta-analysis was conducted on the basis of a guideline for the systematic review of prediction models \[[@pone.0208563.ref018]\]. The results were reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocols (PRISMA-P) 2015 statement \[[@pone.0208563.ref019]\]. This systematic review was registered at PROSPERO (CRD42017070424).

Criteria for considering studies for this review {#sec007}
------------------------------------------------

### Type of studies {#sec008}

We included clinical trials, cohort and case-control studies. Case-reports, case-series, reviews and editorials were excluded.

*Participants*. Participants were hospitalized pregnant and postpartum women (to 6 weeks after delivery) in acute care hospitals. Patients in outpatient clinics or emergency rooms were excluded.

### Index models {#sec009}

Prediction models derived from general hospitalized pregnant and postpartum populations or from critically ill patient populations (e.g. SAPS, APACHE, MPM and SOFA)\[[@pone.0208563.ref006]--[@pone.0208563.ref010]\]. Models focusing on only specific diagnoses (e.g. preeclampsia, postpartum hemorrhage) were excluded due to their limited generalizability to all obstetric patients \[[@pone.0208563.ref012],[@pone.0208563.ref013]\]. We excluded indices that focused only upon pre-existing comorbidity indices as we have previously investigated their predictive performance in obstetric populations \[[@pone.0208563.ref016]\].

### Primary outcome of index models {#sec010}

Maternal mortality (death during pregnancy and up to 42 days after delivery or termination of pregnancy).

Search methods for identification of studies {#sec011}
--------------------------------------------

### Electronic search {#sec012}

MEDLINE, EMBASE (OvidSP) and Scopus were searched systematically for eligible studies, from their inception to May 2017 ([S1 File](#pone.0208563.s003){ref-type="supplementary-material"}), containing three sets of terms reflecting the research question: the models (index risk prediction models), the target condition (maternal critical illness or death), and the patient population (pregnant and postpartum women). Known models were included as a key word in a broader search strategy ([S1 File](#pone.0208563.s003){ref-type="supplementary-material"}) \[[@pone.0208563.ref006]--[@pone.0208563.ref010]\]. No language restriction was made.

### Searching other resources {#sec013}

In addition to identified articles retrieved from electronic databases, a citation search was performed in Web of Science to identify other articles that cited the identified articles above. A manual search was conducted from the reference lists of the Web of Science identified articles. Lastly, experts (SL, JGR) in the field were contacted to identify unpublished studies or studies that may not have been captured in MEDLINE, EMBASE and Scopus.

Data collection and analysis {#sec014}
----------------------------

### Selection of studies {#sec015}

Inclusion criteria: 1) study reports performance of a mortality risk prediction model 2) while pregnant or within 42 days of delivery or termination of the pregnancy; and, 3) among patients admitted to an acute care hospital.

Exclusion criteria: 1) study design was a case-report, case-series, reviews or editorials; 2) patient population was pregnant or postpartum women with a specific diagnosis (e.g. only pre-eclamptic women); or, 3) indices including only pre-existing comorbid conditions.

The two independent reviewers (KA, RD) scanned the titles and abstracts of every record retrieved to determine whether the article was relevant, according to the above eligibility criteria. The full text of potentially eligible articles was then retrieved. The reference lists of retrieved articles were also searched for additional citations. Two reviewers (KA, RD) independently assessed and determined the eligibility of studies. Disagreement was resolved by discussion and, when necessary, a third reviewer (RAF) assisted in adjudicating a final decision.

### Data extraction and management {#sec016}

Reviewers used standardized, piloted data forms to independently extract data from all eligible studies. Each data element was compared between primary and secondary reviewers. Any discrepancies were resolved by discussion or adjudication by the third reviewer. Each study was described by general information (title, journal, year, publication status and study design \[prospective or retrospective\]), descriptors (number of included patients, age, country, subgroups, type of risk prediction model, and stated purpose of the model), reference information (clinical follow-up, mortality rate) and descriptors relevant for assessing the fitness of the model for its intended use: 1) Discrimination---the area under the receiver operating characteristic curve (AUC) or the equivalent c-statistic with 95% confidence interval (CI) or standard error (SE); and, if the AUC or c-statistic was not reported, other operational statistics such as sensitivity and specificity or positive and negative predictive values were recorded when available; 2) Calibration---information on the predicted versus observed mortality ratio is presented as the Standardized Mortality Ratio \[SMR\] (i.e. observed mortality divided by predicted mortality where SMR \< 1 reflects an overestimation of the outcome and SMR \> 1 reflects underestimation of the outcome) and goodness-of-fit statistics (e.g. Hosmer-Lemeshow \[H-L\] goodness-of-fit test) \[[@pone.0208563.ref020]\]. The corresponding author of the original study was contacted to provide missing data.

We used a recently developed reporting system of prediction models in systematic reviews (Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) \[[@pone.0208563.ref021],[@pone.0208563.ref022]\] and extracted 22 data components for each study in the form of a TRIPOD checklist.

### Assessment of methodological quality {#sec017}

There is no single standard for the assessment of quality for prediction or prognostic studies\[[@pone.0208563.ref023],[@pone.0208563.ref024]\]. However, PROBAST ([P]{.ul}rediction model study [R]{.ul}isk [O]{.ul}f [B]{.ul}ias [A]{.ul}ssessment [T]{.ul}ool), a new tool for assessing the methodological quality of risk prediction models was employed \[[@pone.0208563.ref025]\]\[[Fig 1](#pone.0208563.g001){ref-type="fig"}\]. The usability (an actionable recommendation) of a risk prediction model is determined in the following manner\[[@pone.0208563.ref025]\]. First, the risk of bias and any concerns of applicability *(whether the model fits the research question*: *i*.*e*. *what is the most reliable and best-validated risk adjustment and outcome prediction tool for hospitalized pregnant and postpartum women*?*)* of the model to the intended patient population are noted. Second, the model's predictive performance (i.e. discrimination and calibration) is considered. Although PROBAST does not specify how good discrimination and calibration should be, generally AUCs higher than or equal to 0.8 for evaluating discrimination are good and an SMR of approximately 1.0 for evaluating calibration is considered as excellent. Calibration can be described in other forms as well---such as graphic plots or according to the Hosmer-Lemeshow statistic. Third, if a risk prediction model has a low risk of bias and low concern about applicability, and is accompanied by good predictive performance, we conclude that the model is quite "usable" (i.e. usability = "Yes"). If studies lack assessment of either discrimination or calibration but are judged to be at low risk of bias and with minimal concerns of applicability, then we have designated usability as "maybe" (a modified definition from PROBAST). However, even when models with low concerns of applicability are applied, subtleties of the original population for model development should still be considered. For example, a model developed from either an obstetric or a non-obstetric population may perform less well if applied to a different population. as might a model developed primarily for critically ill patients or non-critically ill patients because data elements often differ substantially in each setting.

![Box summary of PROBAST ([P]{.ul}rediction model study [R]{.ul}isk [O]{.ul}f [B]{.ul}ias [A]{.ul}ssessment [T]{.ul}ool).](pone.0208563.g001){#pone.0208563.g001}

### Statistical analysis, data synthesis and meta-analysis {#sec018}

The performance of each index was reported as per the original study using the AUC or c-statistic with 95% confidence intervals (CI) or standard error (SE) for discrimination, and standardized mortality ratio or the H-L goodness-of-fit test statistic for calibration \[[@pone.0208563.ref021],[@pone.0208563.ref022],[@pone.0208563.ref025]\]. A meta-analysis was performed if at least three studies evaluating a prediction model were available and reported on the AUC with 95% CIs or SE, or if the AUC could be calculated \[[@pone.0208563.ref018]\]. The AUC was pooled on the logit scale and the standard errors of the logit transformed AUC were derived from equations previously summarized \[[@pone.0208563.ref018]\]. We then summarized the AUC using the inverse variance method random-effects model, estimated with restricted maximum likelihood and Hartung-Knapp-Sidik-Jonkman adjustment to generate 95% CIs \[[@pone.0208563.ref018],[@pone.0208563.ref026]\].

Clinical heterogeneity across included studies was assessed by examining details of participants and baseline characteristics. The main sources of heterogeneity we expected to encounter related to differences in patients' baseline characteristics, care delivery and outcomes. The I^2^ statistic was used to explore statistical heterogeneity, defined as moderate when I^2^ = 50--74% and high for I^2^ ≥75%. We planned that if there were more than 10 studies assessing a distinct prediction model for meta-analyses, funnel plots would be drawn to assess the possibility of publication bias \[[@pone.0208563.ref027]\]. Statistical computations were undertaken using R version 3.4.0 (Free Software Foundation) with R package (meta).

### Sensitivity and subgroup analyses {#sec019}

Only one sensitivity analysis was pre-planned and included a sub-set of studies, restricted to include those of higher methodological quality (i.e. low risk of bias). One *post-hoc* sensitivity analysis was conducted according to mortality rate: low (under 1%); moderate (to 10%); high to 20%); and very high (greater than 20%).

Two *post-hoc* subgroup analyses were conducted, to investigate high heterogeneity across the eligible studies. One was to separate the all studies into high-income countries, low-income countries or mixed income-countries. The other was to divide the studies into study setting: ICUs or obstetric general wards.

Results {#sec020}
=======

Our initial search of MEDLINE, EMBASE and Scopus retrieved 9,710 citations, 8,935 of which remained after removal of duplications ([Fig 2](#pone.0208563.g002){ref-type="fig"}). Screening of titles and abstracts resulted in 74 relevant articles for which the manuscript full text was assessed for final eligibility. An additional 11 articles were identified through the reference lists and citation tracking of 316 relevant articles with use of Web of Science. Finally, 38 studies of 12 prediction models met inclusion criteria (Tables [1](#pone.0208563.t001){ref-type="table"} and [2](#pone.0208563.t002){ref-type="table"}, Figs [3](#pone.0208563.g003){ref-type="fig"} and [4](#pone.0208563.g004){ref-type="fig"}, and [S1 Table](#pone.0208563.s001){ref-type="supplementary-material"}) \[[@pone.0208563.ref004],[@pone.0208563.ref017],[@pone.0208563.ref036]--[@pone.0208563.ref045],[@pone.0208563.ref028],[@pone.0208563.ref046]--[@pone.0208563.ref055],[@pone.0208563.ref029],[@pone.0208563.ref056]--[@pone.0208563.ref063],[@pone.0208563.ref030]--[@pone.0208563.ref035]\]. The TRIPOD checklist of all 38 eligible articles is available on request ([S2 File](#pone.0208563.s004){ref-type="supplementary-material"}).

![Study selection process (PRISMA flow).](pone.0208563.g002){#pone.0208563.g002}

![Characteristics of predictive models originally developed from obstetric populations.\
\*PROBAST does not currently provide a "Maybe" option; however, we have added this term for perceived intermediate/potentially usable models for pregnant and post-partum populations. \*\*for at least one of the WHO criteria.](pone.0208563.g003){#pone.0208563.g003}

![Characteristics of predictive models originally developed from non-obstetric population.\
\* Results were inconsistent across the full number of studies examining this model. \*\* Sensitivity analysis showed good discrimination and calibration, although results were inconsistent across the full number of studies examining this model. \*\*\*Due to concern of a high risk of bias due to a low SMR.](pone.0208563.g004){#pone.0208563.g004}

10.1371/journal.pone.0208563.t001

###### The number and setting of eligible studies in each prediction model, and original population and setting for development of each study.

![](pone.0208563.t001){#pone.0208563.t001g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                       Original patient population   Original setting                                       External Validation in another Obstetric population\
                                                                                                                                                                                            (number of studies)
  ---------------------------------------------------------------------------------------------------- ----------------------------- ------------------------------------------------------ ------------------------------------------------------
  Acute Physiology And Chronic Health Evaluation score II & III[\*](#t001fn002){ref-type="table-fn"}   Non-obstetric                 ICU                                                    21

  Simplified Acute Physiology Score 2 & 3                                                              Non-obstetric                 ICU                                                    9

  Sepsis-related Organ Failure Assessment                                                              Non-obstetric                 ICU                                                    5

  Mortality Prediction Model 2 & 3                                                                     Non-obstetric                 ICU                                                    3

  World Health Organization criteria                                                                   Obstetric                     ICU                                                    1

  Obstetric Early Warning Score                                                                        Obstetric                     ICU                                                    1

  Collaborative Integrated Pregnancy High-dependency Estimate of Risk                                  Obstetric                     ICU                                                    0

  Maternal Severity Index                                                                              Obstetric                     General ward                                           2

  Maternal Mortality Score                                                                             Obstetric                     General ward [\*\*](#t001fn003){ref-type="table-fn"}   0
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ICU = intensive care unit

\* include updated tool from original model

\*\* Hospitals in developing countries

10.1371/journal.pone.0208563.t002

###### Summary of 38 eligible articles.

![](pone.0208563.t002){#pone.0208563.t002g}

  Prediction models                                                                                                                                                                                                                                 Country            Study design                                                     Study period                              Study population      Sample size                                     Outcomes
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------ ---------------------------------------------------------------- ----------------------------------------- --------------------- ----------------------------------------------- -----------------------------------------------------
  Collaborative Integrated Pregnancy High-dependency Estimate of Risk \[Payne\]                                                                                                                                                                     17 countries       Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        2000--12                                  ICU                   477                                             Antepartum and postpartum mortality
  Combined WHO criteria: laboratory and management criteria \[Cecatti\]                                                                                                                                                                             Brazil             Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        2002--7                                   All hospitalization   673                                             ICU mortality
  Maternal Severity Index \[Souza\][\*\*\*\*\*](#t002fn006){ref-type="table-fn"}                                                                                                                                                                    Brazil             Prospective cohort[\*\*](#t002fn003){ref-type="table-fn"}        2009--10                                  All hospitalization   82,388                                          Hospital mortality
  Maternal Severity Index \[Souza\]                                                                                                                                                                                                                 29 countries       Cross-sectional[\*](#t002fn002){ref-type="table-fn"}             2010--11                                  All hospitalization   314,623                                         Hospital mortality
  Maternal Severity Index \[Haddad\][\*\*\*\*\*](#t002fn006){ref-type="table-fn"}                                                                                                                                                                   Brazil             Cross-sectional[\*](#t002fn002){ref-type="table-fn"}             2009--10                                  All hospitalization   9,555                                           Hospital mortality
  Obstetric early warning score, Modified Early Obstetric Warning System, the confidential enquiries into maternal death Obstetric EWS, the royal college of physician\'s non-obstetric NEWS \[Carle\][\*\*\*\*](#t002fn005){ref-type="table-fn"}   United Kingdom     Retrospective cohort[\*\*](#t002fn003){ref-type="table-fn"}      1995--2008                                ICU                   4,440                                           ICU mortality
  Obstetric early warning score \[Paternina-Caicedo\]                                                                                                                                                                                               Colombia           Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        2006--11                                  ICU                   702                                             Antepartum and postpartum mortality
  Maternal mortality Score \[Huchon\]                                                                                                                                                                                                               Senegal and Mali   Prospective cohort[\*\*](#t002fn003){ref-type="table-fn"}        2007--8                                   All hospitalization   43,624 for development, 46,328 for validation   Hospital mortality
  SOFA \[Kallur\]                                                                                                                                                                                                                                   India              Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        2011--12                                  ICU                   69                                              Mortality [\*\*\*](#t002fn004){ref-type="table-fn"}
  SOFA \[Oliveira-Neto\]                                                                                                                                                                                                                            Brazil             Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        2002--7                                   ICU                   673                                             ICU mortality
  SOFA \[Jain\]                                                                                                                                                                                                                                     India              Prospective cohort[\*](#t002fn002){ref-type="table-fn"}          2010--11                                  ICU                   90                                              ICU mortality
  APACHE II, SOFA \[Simsek\]                                                                                                                                                                                                                        Turkey             Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        1999--2009                                ICU                   63                                              ICU mortality
  APACHEII, SOFA \[Vasquez\]                                                                                                                                                                                                                        Argentina          Prospective cohort[\*](#t002fn002){ref-type="table-fn"}          2012                                      ICU                   362                                             Hospital mortality
  APACHE II, SAPS2, MPM2 \[el-Solh\]                                                                                                                                                                                                                United States      Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        1989--95                                  ICU                   93                                              Antepartum and postpartum mortality
  MPM2 \[Gupta\]                                                                                                                                                                                                                                    India              Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        2009--10                                  ICU                   24                                              ICU mortality
  SAPS2, 3 MPM2, 3 \[Rojas-Suarez\]                                                                                                                                                                                                                 Colombia           Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        2006--11                                  ICU                   726                                             Mortality [\*\*\*](#t002fn004){ref-type="table-fn"}
  APACHE II, SAPS2, APACHE III \[Hazelgrove\]                                                                                                                                                                                                       England            Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        1994--6                                   ICU                   210                                             Mortality [\*\*\*](#t002fn004){ref-type="table-fn"}
  SAPS2 \[Gombar\]                                                                                                                                                                                                                                  India              Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        2007--12                                  ICU                   151                                             Mortality [\*\*\*](#t002fn004){ref-type="table-fn"}
  APACHE II, SAPS2 \[Lapinsky\]                                                                                                                                                                                                                     6 countries        Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        1994--8                                   ICU                   332                                             Hospital mortality
  APACHE II SAPS2 \[Mjahed\]                                                                                                                                                                                                                        Morocco            Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        1995--2002                                ICU                   364                                             Hospital mortality
  SAPS2 \[Gilbert\]                                                                                                                                                                                                                                 United States      Cohort, unknown pro/retro[\*](#t002fn002){ref-type="table-fn"}   1991--1998                                ICU                   233                                             Hospital mortality
  SAPS2 \[Tempe\]                                                                                                                                                                                                                                   India              Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        2002--04                                  ICU                   57                                              Hospital mortality
  SAPS2 \[Togal\]                                                                                                                                                                                                                                   Turkey             Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        2006--09                                  ICU                   73                                              Mortality [\*\*\*](#t002fn004){ref-type="table-fn"}
  APACHE II \[Afessa\]                                                                                                                                                                                                                              United States      Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        1991--1998                                ICU                   74                                              Hospital mortality
  APACHE II \[Aldawood\]                                                                                                                                                                                                                            Saudi Arabia       Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        1999--2009                                ICU                   75                                              ICU mortality
  APACHE II \[Bhadade\]                                                                                                                                                                                                                             India              Prospective cohort[\*](#t002fn002){ref-type="table-fn"}          2009--10                                  ICU                   122                                             ICU mortality
  APACHE II \[Harde\]                                                                                                                                                                                                                               India              Prospective cohort[\*](#t002fn002){ref-type="table-fn"}          2011--12                                  ICU                   61                                              Mortality [\*\*\*](#t002fn004){ref-type="table-fn"}
  APACHE II \[Harrison\][\*\*\*\*](#t002fn005){ref-type="table-fn"}                                                                                                                                                                                 United Kingdom     Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        1995--2003                                ICU                   1,902                                           Hospital mortality
  APACHE II \[Karnad\]                                                                                                                                                                                                                              India              Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        1997--2001                                ICU                   453                                             Mortality [\*\*\*](#t002fn004){ref-type="table-fn"}
  APACHE II \[Lenz\]                                                                                                                                                                                                                                Austria            Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        March 1996- Oct 2001, Nov 2004-Jun 2005   ICU                   80                                              Hospital mortality
  APACHE II \[Lewinsohn\]                                                                                                                                                                                                                           Israel             Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        non specific 8 years                      ICU                   58                                              Hospital mortality
  APACHE II \[Mahutte\]                                                                                                                                                                                                                             Canada             Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        1992--97                                  ICU                   131                                             ICU mortality
  APACHE II \[Muench\]                                                                                                                                                                                                                              United States      Prospective cohort[\*](#t002fn002){ref-type="table-fn"}          Non specific 2 years                      ICU                   34                                              Mortality [\*\*\*](#t002fn004){ref-type="table-fn"}
  APACHE II \[Tang\]                                                                                                                                                                                                                                China              Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        1998--1995                                ICU                   49                                              ICU mortality
  APACHE II \[Thakur\]                                                                                                                                                                                                                              United States      Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        2006--12                                  ICU                   69                                              ICU mortality
  APACHE II, updated APACHE II \[Paternina-Caicedo\]                                                                                                                                                                                                Colombia           Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        2006--11                                  ICU                   654                                             ICU mortality
  APACHE II \[Vasquez\]                                                                                                                                                                                                                             Argentina          Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        1998--2005                                ICU                   161                                             ICU mortality
  APACHE III \[Crozier\]                                                                                                                                                                                                                            Australia          Retrospective cohort[\*](#t002fn002){ref-type="table-fn"}        2006--8                                   ICU                   60                                              Hospital mortality

Abbreviations: WHO: World Health Organization, SOFA: Sequential Organ Failure Assessment, APACHE: Acute Physiology And Chronic Health Evaluation, SAPS: Simplified Acute Physiology Score, MPM: Mortality Probability Model

\* validation study

\*\* development and validation study

\*\*\* without specific time period specified

\*\*\*\* Same cohort from ICNARC (Intensive Care National Audit and Research Center in United Kingdom)

\*\*\*\*\*Same cohort from The Brazilian Network for Surveil- lance of Severe Maternal Morbidity

Of these 38, 4 studies both developed *and* validated their model ([Table 1](#pone.0208563.t001){ref-type="table"}) \[[@pone.0208563.ref030],[@pone.0208563.ref037],[@pone.0208563.ref054],[@pone.0208563.ref063]\], and the remainder (n = 34) were primarily validation studies. Most studies (n = 36) employed a cohort design (prospective in 7, retrospective in 28 and unknown in 1) and 2 used a cross-sectional design ([Table 2](#pone.0208563.t002){ref-type="table"}). Nine studies investigated more than one prediction model in the study. Samples size in included studies ranged from 24 to more than 80,000 subjects. The most commonly reported primary outcome was hospital mortality (n = 14), followed by ICU mortality (n = 13), although eight studies did not specify timing or place of death. Mortality varied across the studies, with an average rate 10.4%, ranging from 0 to 41.7% ([Table 2](#pone.0208563.t002){ref-type="table"}, [Fig 3](#pone.0208563.g003){ref-type="fig"} and [Fig 4](#pone.0208563.g004){ref-type="fig"}). Most studies (n = 16) were from a single developed country, 4 were multi-country studies, and 18 were from developing countries.

No uniform measure was reported to quantify the predictive performance (ability to predict outcomes of interest) of eligible models ([Fig 3](#pone.0208563.g003){ref-type="fig"} and [Fig 4](#pone.0208563.g004){ref-type="fig"}). Among 20 studies reporting AUC, values ranged from 0.77 to 0.98; 18 studies reported AUCs higher than 0.8, indicating good discriminative performance. SMR was the most commonly reported form of calibration (n = 26), ranging from 0 to 1.57. Only 4 studies reported the Hosmer-Lemeshow goodness-of-fit test \[[@pone.0208563.ref050],[@pone.0208563.ref053],[@pone.0208563.ref054],[@pone.0208563.ref061]\]. Four studies investigated classification measures (e.g. sensitivity and specificity) for a particular cut point of each model with or without reporting discrimination and calibration \[[@pone.0208563.ref004],[@pone.0208563.ref031],[@pone.0208563.ref038],[@pone.0208563.ref043]\] ([Fig 3](#pone.0208563.g003){ref-type="fig"} and [Fig 4](#pone.0208563.g004){ref-type="fig"}).

The methodological quality for each study as determined by PROBAST ([Fig 3](#pone.0208563.g003){ref-type="fig"} and [Fig 4](#pone.0208563.g004){ref-type="fig"}, and [S3 File](#pone.0208563.s005){ref-type="supplementary-material"}) is summarized by a measure of model *Usability* \[[@pone.0208563.ref025]\] \[[Fig 1](#pone.0208563.g001){ref-type="fig"}\].

Predictive models originally developed from obstetric populations {#sec021}
-----------------------------------------------------------------

Five models were developed and validated to identify obstetric patients at risk of death using a combination of comorbid health conditions, clinical characteristics, physiological and laboratory based data: the Collaborative Integrated Pregnancy High-dependency Estimate of Risk (CIPHER), the World Health Organization (WHO) Criteria, Maternal Severity Index, Obstetric Early Warning Score and the Maternal Mortality Score \[[@pone.0208563.ref030],[@pone.0208563.ref031],[@pone.0208563.ref037],[@pone.0208563.ref054],[@pone.0208563.ref063]\] ([Table 2](#pone.0208563.t002){ref-type="table"}, Figs [3](#pone.0208563.g003){ref-type="fig"} and [5](#pone.0208563.g005){ref-type="fig"}).

![Box summary of variables of predictive models originally developed from obstetric populations.](pone.0208563.g005){#pone.0208563.g005}

The Collaborative Integrated Pregnancy High-dependency Estimate of Risk was developed for predicting mortality and prolonged organ support of pregnant and postpartum women. The cohort included individuals in Intensive Care Units of 11 high-, middle- and low-income countries, with an overall mortality rate 9.6% \[[@pone.0208563.ref063]\]. The final model contains 10 predictors: maternal age, surgery in the preceding 24 hours, systolic blood pressure, Glasgow Coma Scale, serum bilirubin, activated partial thromboplastin time, serum creatinine, potassium, sodium and arterial blood gas pH. Discrimination (AUC: 0.823, 95% CIs 0.811--0.835) and calibration (Graphic plot \[intercept---0.09, slope 0.92\]) were internally validated with a bootstrapped sample---in a graphic plot, perfect calibration shows a slope of 1 and intercept of 0. There was no external validation.

The WHO introduced criteria consisting of patient characteristics, vital signs, and physiological and laboratory data to predict maternal severe morbidity. Cecatti et al assessed laboratory- and management-based markers of severity of illness (for example, use of vasopressors, dialysis, ventilation, transfusion, need for hysterectomy, receipt of cardiopulmonary resuscitation) on the risk of maternal death \[[@pone.0208563.ref031]\]. Using a combined count of all events, sensitivity and specificity (with at least one criteria of severe morbidity) for predicting death was assessed. Mortality rate of the cohort was 2.67%. Subsequently, Souza et al. validated the WHO criteria's predictive ability using a different dataset in a distinct middle-income country \[[@pone.0208563.ref054]\]. The Maternal Severity Index was developed on the basis of this validation, incorporating the WHO criteria in addition to other markers of severe illness, for those who were in general wards and also Intensive Care Units \[[@pone.0208563.ref054]\]. The Maternal Severity Index was subsequently externally validated using multi-national cohorts, demonstrating a good AUC (0.82, 95% CIs 0.78--0.86) and SMR (1.02) \[[@pone.0208563.ref029],[@pone.0208563.ref049]\]. In total, 3 studies investigated the Maternal Severity Index, with mortality ranging from 0.15 to 1.47%.

The Obstetric Early Warning Score incorporates vital signs, level of consciousness and oxygen requirements. It was developed and internally validated in the United Kingdom with mortality 1.6% and an AUC of 0.957 (95% CIs 0.923--0.991) for predicting death \[[@pone.0208563.ref030]\]. The study was considered to be at high risk of bias due to a number of excluded participants from the final model. There was high concern of applicability to the obstetric patient population in general wards because the model was developed on the basis of ICU patients and mortality in ICU rather than hospital patients and hospital mortality. Recently, an external validation was performed, demonstrating good predictive ability (AUC: 0.84, 95% CIs 0.75--0.92) for mortality among obstetrics patients, with a mortality rate 4.1% \[[@pone.0208563.ref061]\]. However, calibration has not yet been evaluated.

The Maternal Mortality Score uses 9 clinical and social conditions, was developed in low- and middle-income countries, and showed good discrimination ability in the development (AUC 0.89, 95% CIs 0.87--0.91, mortality rate: 0.69%) and validation (AUC 0.90, 95% CIs 0.89--0.92, mortality rate: 0.79%) cohorts \[[@pone.0208563.ref037]\]. The Maternal Mortality Score has only been validated by one study, and calibration has not yet been evaluated.

Of all models developed and validated to identify obstetric patients at risk of death using a combination of comorbid health conditions, clinical characteristics, physiological and laboratory based data, the Collaborative Integrated Pregnancy High-dependency Estimate of Risk and the Maternal Severity Index were developed/validated from studies with a low risk of bias and low concern of applicability of the model to obstetric populations for predicting maternal death, leading to a designation of high "usability" \[[@pone.0208563.ref029],[@pone.0208563.ref037],[@pone.0208563.ref054],[@pone.0208563.ref063]\] ([Fig 3](#pone.0208563.g003){ref-type="fig"}).

Models originally developed primarily from non-obstetric patient populations {#sec022}
----------------------------------------------------------------------------

Thirty studies explored 7 predictive models developed primarily from non-obstetric patient populations---the Simplified Acute Physiology Score 2 and 3, Acute Physiology and Chronic Health Evaluation Score 2 and 3, Sequential Organ Failure Assessment, and the Mortality Probability Model, versions 2 and 3) \[[@pone.0208563.ref004],[@pone.0208563.ref017],[@pone.0208563.ref040]--[@pone.0208563.ref049],[@pone.0208563.ref028],[@pone.0208563.ref050]--[@pone.0208563.ref053],[@pone.0208563.ref055]--[@pone.0208563.ref057],[@pone.0208563.ref059],[@pone.0208563.ref060],[@pone.0208563.ref062],[@pone.0208563.ref032]--[@pone.0208563.ref036],[@pone.0208563.ref038],[@pone.0208563.ref039]\] ([Fig 4](#pone.0208563.g004){ref-type="fig"})---that were initially developed from non-obstetric critically ill patient populations and incorporated *patient characteristics*, *comorbidities*, *physiological and laboratory-based data*. The AUC across these 7 models was near 0.80, demonstrating good discriminative ability. Most studies (n = 25) reported the standardized mortality ratio for calibration, which varied from 0 to 1.57, indicating that some models under-estimate and others over-estimate true mortality ([Fig 4](#pone.0208563.g004){ref-type="fig"}). Six studies of the Acute Physiology and Chronic Health Evaluation II \[[@pone.0208563.ref004],[@pone.0208563.ref017],[@pone.0208563.ref032],[@pone.0208563.ref036],[@pone.0208563.ref050],[@pone.0208563.ref053]\], 6 studies of the Simplified Acute Physiology Score 2 \[[@pone.0208563.ref017],[@pone.0208563.ref032],[@pone.0208563.ref033],[@pone.0208563.ref036],[@pone.0208563.ref042],[@pone.0208563.ref045]\], 4 studies of the Sequential Organ Failure Assessment \[[@pone.0208563.ref004],[@pone.0208563.ref038],[@pone.0208563.ref041],[@pone.0208563.ref060]\] and 3 studies of the Mortality Probability Model \[[@pone.0208563.ref032],[@pone.0208563.ref034],[@pone.0208563.ref042]\] were pooled in separate meta-analyses \[[Fig 6](#pone.0208563.g006){ref-type="fig"}\]. SOFA had the highest discrimination followed by SAPS2 and APACHE II and MPM2. None of models originally developed primarily from non-obstetric patient populations had a designation of high "usability".

![Pooled AUC of APACHE II, SAPS, SOFA and MPM2.](pone.0208563.g006){#pone.0208563.g006}

Sensitivity analyses {#sec023}
--------------------

A preplanned sensitivity analysis was performed, among 9 studies with low risk of bias and low concern of applicability \[[@pone.0208563.ref004],[@pone.0208563.ref032]--[@pone.0208563.ref034],[@pone.0208563.ref039],[@pone.0208563.ref045],[@pone.0208563.ref057],[@pone.0208563.ref058],[@pone.0208563.ref060]\]. Five studies evaluated APACHE II \[[@pone.0208563.ref004],[@pone.0208563.ref032],[@pone.0208563.ref039],[@pone.0208563.ref057],[@pone.0208563.ref058]\], 4 studies evaluated SAPS 2 \[[@pone.0208563.ref032],[@pone.0208563.ref033],[@pone.0208563.ref045],[@pone.0208563.ref057]\], 2 studies evaluated SOFA \[[@pone.0208563.ref004],[@pone.0208563.ref060]\] and 2 studies evaluated MPM 2 \[[@pone.0208563.ref032],[@pone.0208563.ref034]\]. APACHE II showed good discrimination, but over-estimated death. The MPM 2 showed good discrimination, but underestimated death. SOFA showed good discrimination, but calibration was not investigated. AUCs of SAPS 2 were pooled in this sensitivity analysis. The SAPS 2 summary AUC was 0.84 (95% CIs \[0.92--0.94\] and I^2^ = 0%) with good discrimination, and calibration \[[S1 Fig](#pone.0208563.s002){ref-type="supplementary-material"}\].

A *post-hoc* sensitivity analysis was conducted according to mortality rates. AUCs were not pooled in this analysis because of the limited number of studies for each model. In studies from countries with low mortality--less than 1%---the Maternal Severity Index is the only model that is externally validated. In studies from countries with moderate mortality rates--less than 10%---all predictive models originally developed from non-obstetric population, except SAPS3, were investigated. However, the CIPHER model is the only well validated model for both discrimination and calibration. Only predictive models developed from non-obstetric population were investigated in studies with high and very high mortality. Predictive performance (i.e. discrimination and calibration) of models in studies with high and very high mortality were inconsistent across studies.

Subgroup analyses {#sec024}
-----------------

Two *post-hoc* subgroup analyses were carried out. In predictive models developed from obstetric population, the CIPHER model and the Maternal Severity Index were investigated in both high- and low-income countries. Studies for predictive models developed from non-obstetric populations were well balanced between high- and low-income countries, and predictive performance seemed similar. The Maternal Severity Index was the only model that was investigated in general obstetric ward patients; therefore, it was difficult to estimate how other settings might affect predictive performance of the models.

Discussion {#sec025}
==========

Main findings {#sec026}
-------------

This systematic review identified 38 studies that developed and/or validated 12 models for predicting mortality among hospitalized pregnant and postpartum women. The Collaborative Integrated Pregnancy High-dependency Estimate of Risk (CIPHER) for hospitalized critically ill obstetric populations, and the Maternal Severity Index for hospitalized general obstetric populations have good discrimination, calibration, were developed from studies with a low risk of bias and internally and/or externally validated for critically ill pregnant and postpartum women. Prediction models developed from non-obstetric patients and from general ICU patient populations have very good discrimination but are at risk of over- or under-estimation of true mortality.

Interpretations {#sec027}
---------------

Maternal death is rare event. Hence, predictive models for maternal death seem to show high discriminative performance. In this context, calibration is important in assessing overall predictive performance. However, most of eligible studies in this review reported SMR, which is known to be a relatively crude measure of calibration \[[@pone.0208563.ref018]\] and ideally should be considered across the full range of outcome rates \[[@pone.0208563.ref064]\]. The Hosmer-Lemeshow goodness-of-fit test is very sensitive to sample size and also therefore an imperfect measure of calibration \[[@pone.0208563.ref065]\]. Therefore, calibration in models reporting SMR and Hosmer-Lemeshow goodness-of-fit test need to be interpreted in the context of the setting of the study, in addition to the setting of its application.

The wide range of mortality of the eligible 38 studies helps to explain high heterogeneity we found for various prediction models, across the studies. Also, the studies were assessed in different clinical settings and among patients of varying initial severity of illness, making comparability of predictive performance challenging. For example, a predictive model developed in a country where mortality is high might falsely under- or over-estimate mortality in a country where mortality is much lower, or vice versa. On the other hand, the average mortality among studies of predictive models originally developed from obstetric populations was higher than one from non-obstetric populations. This might explain why the calibration among studies of predictive models from non-obstetric populations appears to be worse than one from obstetric populations.

Implications {#sec028}
------------

In observational studies, a risk adjustment tool is essential to help take into account characteristics (e.g. the severity of a patient's illness) that may influence or confound an attempt to estimate the magnitude and significance of new factor of interest on a *cohort of patients'* clinical outcome such as death. Both CIPHER and the Maternal Severity Index models might also be used to help risk adjust mortality differences between health facilities as part of quality assurance and improvement initiatives \[[@pone.0208563.ref029],[@pone.0208563.ref054],[@pone.0208563.ref063]\].

However, none of the indices studied have sufficient predictive ability to be used in determining the outcome of an *individual* obstetric patient. A risk prediction model revealing a 90% risk of death in a selected population of 100 pregnant or post-partum women cannot differentiate which *individual* 10 women will survive and which will die. That is, there is a risk of underestimating risk in low-risk patients, and of overestimating risk in high-risk patients. Therefore, estimates based on risk prediction models should not directly affect the decisions for withdrawing or withholding management of individual seriously ill pregnant or postpartum women. However, despite uncertainty of predictive performance in assessing individual risk, prediction models may help to identify pregnant and peri-partum women at high risk of critical illness or death and stimulate increased monitoring or preventive measures.

Risk prediction models developed from non-obstetric patient populations should generally not be applied to obstetric patient populations, *if a better alternative exists*. The CIPHER model for hospitalized critically ill obstetric populations, and the Maternal Severity Index for hospitalized general obstetric populations are suggested for use, when sufficient data exists. In low/middle income countries, because of the large number of variables required for the models, feasibility is a concern, and therefore, the Maternal Mortality Score may be more appropriate. For future research, investigation of few different prediction models within the same population is the ideal study design, to determine the best model for predicting maternal mortality.

Strengths and limitations {#sec029}
-------------------------

This systematic review has a number of strengths. This is the first systematic review of risk prediction models for maternal mortality in obstetric populations. We followed the most recent guideline of systematic reviews for risk prediction models \[[@pone.0208563.ref018]\] and the PRISMA-P 2015 statement ([S4 File](#pone.0208563.s006){ref-type="supplementary-material"}) \[[@pone.0208563.ref019]\]. We employed a formal and broad search strategy, without language restriction and differentiated between risk prediction models for obstetric and non-obstetric populations. We used a robust tool to identify studies at risk of bias using the [P]{.ul}rediction model study [R]{.ul}isk [O]{.ul}f [B]{.ul}ias [A]{.ul}ssessment [T]{.ul}ool \[[@pone.0208563.ref025]\], which allowed us to conduct sensitivity analyses on the most applicable studies for obstetric populations. Next, we have developed our systematic review according to the ROBIS guidelines for detecting bias in systematic reviews ([S5 File](#pone.0208563.s007){ref-type="supplementary-material"}) \[[@pone.0208563.ref066]\]. Lastly, our findings are applicable to pregnant and postpartum women who are admitted to either ICUs or acute care wards of general hospitals.

This systematic review also has certain limitations. First, individual patient data from each prediction model evaluation was not available, which precludes an opportunity re-calculate model performance characteristics, and precludes an opportunity to meta-analyze some metrics we evaluated. Second, the data sources used in the various evaluations were derived from diverse clinical settings across and within countries where patient characteristics and clinical practice vary. Yet, this clinical heterogeneity of included studies allows us to make inferences across diverse settings, for patients in an ICU or a hospital. Third, the eligible studies reported mortality at different measurement points (e.g. ICU mortality, hospital mortality), which was challenging to meta-analyze. Fourth, some risk prediction models we identified in the current study could perform differently in certain common diseases of maternal death (e.g. infection) \[[@pone.0208563.ref067]\], although our findings are likely applicable to most general obstetric populations. Fifth, physiology-based predictions models developed from non-obstetric populations may be challenging to apply to pregnant patients because of changes in physiology (heart rate, blood pressure, respiratory rate for example) that occur as a usual course of pregnancy. Importantly, there were a limited number of studies validating prediction models developed from obstetric population.

Conclusion {#sec030}
==========

Mortality risk prediction models developed from obstetric patient populations, such as the Collaborative Integrated Pregnancy High-dependency Estimate of Risk (CIPHER) model and the Maternal Severity Index, have good discrimination and calibration, developed/validated from studies with a low risk of bias, and should be encouraged for use in prospectively designed studies, trials and quality improvement research among critically ill pregnant and postpartum women. While prediction models previously developed from general and non-obstetric patient populations such as the APACHE, MPM, SAPS, and SOFA scores are at some risk of over- or under-estimating mortality, they generally have good discrimination and may reasonably be used when pregnancy-specific models are unavailable.
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AUC

:   area under the receiver operating characteristic curve

SAPS

:   simplified acute physiology score

APACHE

:   acute physiology and chronic health evaluation score

MPM

:   the mortality prediction model

SOFA

:   sequential organ failure assessment

ICU

:   intensive care unit

PRISMA

:   the Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocols

CI

:   confidence interval

SE

:   standard error

SMR

:   Standardized Mortality Ratio

TRIPOD

:   Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis

PROBAST

:   Prediction model study Risk Of Bias Assessment Tool
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:   World Health Organization
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